Last reviewed · How we verify
CEFTIBUTEN
At a glance
| Generic name | CEFTIBUTEN |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1995 |
Approved indications
Common side effects
Key clinical trials
- Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Male and Female Participants 18 to ≤55 Years of Age (PHASE1)
- Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination (PHASE1)
- P1, DDI & MAD PK and Safety Study of Xeruborbactam Oral Prodrug in Combo With Ceftibuten in Healthy Participants (PHASE1)
- VNRX-7145 Drug-Drug Interaction in Healthy Adult Volunteers (PHASE1)
- Ceftibuten/VNRX-7145 in Participants With Varying Degrees of Renal Function (PHASE1)
- Food Effect on Ceftibuten/VNRX-7145 in Healthy Participants (PHASE1)
- Subthreshold Micropulse Laser Therapy (SML) in Retinitis Pigmentosa (NA)
- To Learn How Different Forms of Study Medicine Are Taken up Into the Blood and the Effect of Food on Study Medicine in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CEFTIBUTEN CI brief — competitive landscape report
- CEFTIBUTEN updates RSS · CI watch RSS